Sercan TAK, Murat KOÇ, Ali KUTSAL, Vehbi DOĞAN
Turkish Journal of Medical Sciences - 2026;56(3):778-786
Background/aim: Pulmonary regurgitation following tetralogy of Fallot repair is a common long-term complication requiring pulmonary valve replacement. Injectable bioprosthetic valves offer a less invasive alternative to conventional surgical replacement, but comparative data in pediatric populations remain limited. This study aimed to evaluate short-term and long-term clinical outcomes of injectable pulmonary valve replacement and conventional pulmonary valve replacement in pediatric patients with severe pulmonary regurgitation following tetralogy of Fallot repair. Materials and methods: This retrospective study included 22 pediatric patients who underwent pulmonary valve replacement. Patients were divided into injectable (n = 9) and conventional (n = 13) groups based on anatomical criteria. Primary outcomes included early postoperative parameters and long-term valve function. The mean follow-up duration was 10.5 +/- 2.5 years. Results: Favorable early outcomes were noted in the injectable pulmonary valve replacement cohort, including shorter intensive care unit stay (16.8 +/- 6.2 vs. 37.0 +/- 23.4 h, p = 0.021), reduced mechanical ventilation duration (5.2 +/- 3.9 vs. 15.4 +/- 11.4 h, p = 0.019), decreased chest tube drainage (206.7 +/- 108.2 vs. 513.1 +/- 274.1 mL, p = 0.005), and shorter hospital stay (5.4 +/- 2.4 vs. 8.4 +/- 3.1 days, p = 0.026). Long-term outcomes indicated similar valve function and right ventricular remodeling in the two groups, with excellent freedom from reintervention (100%) during follow-up. Conclusion: Injectable pulmonary valve replacement appears to be a safe alternative, offering favorable early outcomes and long-term valve performance comparable to conventional methods. However, clinical experience and precise patient selection remain critical for achieving optimal results.
